BlossomHill Therapeutics, Inc.
BLSM Nasdaq
SEC CIK 1839970
Follow BlossomHill Therapeutics
Weekly email: filings, results
Net income
−$24M
−50.3% vs same quarter last year
EPS, diluted
−$1.29
+80.3% vs same quarter last year
Operating cash flow
−$22.2M
−91.6% vs same quarter last year
Operating income
−$25.5M
−52.3% vs same quarter last year
Source: SEC XBRL filings · latest filing